Silymarin, from the fruit of Silybum marianum , is known for its hepatoprotective action. The aim of this study was to review the mechanisms of action of the silymarin phytocomplex to expand the possibilities for its application in human health. The search for published articles was carried out on the CAPES Journals Portal platform, which covers worldwide scientific databases. Publications from 2010 to 2022 were included. Of the 311 articles retrieved, 21 were included. The articles discuss the diversity of silymarin’s applications and the possibility of optimizing its bioavailability using drug delivery systems. Silymarin shows promise in numerous diseases, such as liver, kidne y, cardio vascular, respiratory and others. Its antiviral action has been demo nstrated in studies and silymarin has the potential to be used as a complementary therapy in the treatment of many diseases, with the expectation that, in the future, it will be used in therapeutic protocols for exclusive use.
KeywordsSilymarinFlavonoidsPhytotherapeutic Drugs
Marjani, M., Baghaei, P., Kazempour Dizaji, M., Gorji Bayani, P., Fahimi, F., Tabarsi, P., et al. (2016) Evaluation of Hepatoprotective Effect of Silymarin among under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 15, 247-252.
Federico, A., Dallio, M. and Loguercio, C. (2017) Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules, 22, Article 191. https://doi.org/10.3390/molecules22020191
Vargas-Mendoza, N., Madrigal-Santillán, E., Morales-González, A., Esquivel-Soto, J., Esquivel-Chirino, C., García-Luna., et al. (2014) Hepatoprotective Effect of Silymarin. World Journal of Hepatology, 6, 144-149. https://doi.org/10.4254/wjh.v6.i3.144
Esposito, T., Sansone, F., Russo, P., Picerno, P., Aquino, R.P., Gasparri, F., et al. (2019) A Water-Soluble Microencapsulated Milk Thistle Extract as Active Ingredient for Dermal Formulations. Molecules, 24, Article 1547. https://doi.org/10.3390/molecules24081547
Ganesan, P. and Choi, D.K. (2016) Current Application of Phytocompound-Based Nanocosmeceuticals for Beauty and Skin Therapy. International Journal of Nanomedicine, 11, 1987-2007. https://doi.org/10.2147/IJN.S104701
Ni, X. and Wang, H. (2016) Silymarin Attenuated Hepatic Steatosis through Regulation of Lipid Metabolism and Oxidative Stress in a Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD). American Journal of Translational Research, 8, 1073-1081.
Surai, P.F. (2015) Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives. Antioxidants, 4, 204-247. https://doi.org/10.3390/antiox4010204
Avci, H., Epikmen, E.T., İpek, E., Tunca, R., Birincioglu, S.S., Akşit, H., et al. (2017) Protective Effects of Silymarin and Curcumin on Cyclophosphamide-Induced Cardiotoxicity. Experimental and Toxicologic Pathology, 69, 317-327. https://doi.org/10.1016/j.etp.2017.02.002
Devi, K.P., Malar, D.S., Braidy, N., Nabavi, S.M. and Nabavi, S.F. (2017) A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin. Current Drug Targets, 18, 1529-1536. https://doi.org/10.2174/1389450117666161227125121
Onaolapo, A.Y., Abdusalam, S.Z. and Onaolapo, O.J. (2017) Silymarin Attenuates Aspartame-Induced Variation in Mouse Behaviour, Cerebrocortical Morphology and Oxidative Stress Markers. Pathophysiology, 24, 51-62. https://doi.org/10.1016/j.pathophys.2017.01.002
Anestopoulos, I., Sfakianos, A.P., Franco, R., Chlichlia, K., Panayiotidis, M.I., Kroll, D.J., et al. (2017) A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma. Molecules, 22, Article 62. https://doi.org/10.3390/molecules22010062
Gorhe, A., Kulkarni, A., Kandalkar, P. and Jagtap, S. (2020) Silymarin Loaded Novel Drug Delivery for Oral and Topical Administration. Journal of Drug Delivery & Therapeutics, 10, 262-270. https://doi.org/10.22270/jddt.v10i3-s.4125
Abenavoli, L., Capasso, R., Milic, N. and Capasso, F. (2010) Milk Thistle in Liver Diseases: Past, Present, Future. Phytotherapy Research, 24, 1423-1432. https://doi.org/10.1002/ptr.3207
Tvrdy, V., Pourová, J., Jirkovsky, E., Křen, V., Valentová, K. and Mladěnka, P. (2021) Systematic Review of Pharmacokinetics and Potential Pharmacokinetic Interactions of Flavonolignans from Silymarin. Medicinal Research Reviews, 41, 2195-2246. https://doi.org/10.1002/med.21791
Wen, Z., Dumas, T.E., Schrieber, S.J., Hawke, R.L., Fried, M.W. and Smith, P.C. (2008) Pharmacokinetics and Metabolic Profile of Free, Conjugated, and Total Silymarin Flavonolignans in Human Plasma after Oral Administration of Milk Thistle Extract. Drug Metabolism and Disposition, 36, 65-72. https://doi.org/10.1124/dmd.107.017566
Hawke, R.L., Schrieber, S.J., Soule, T.A., Wen, Z., Smith, P.C., Reddy, K.R., et al. (2010) Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients with Chronic Hepatitis C. The Journal of Clinical Pharmacology, 50, 434-449. https://doi.org/10.1177/0091270009347475
Marhol, P., Bednář, P., Kolářová, P., Večeřa, R., Ulrichová, J., Tesařová, E., et al. (2015) Pharmacokinetics of Pure Silybin Diastereoisomers and Identification of Their Metabolites in Rat Plasma. Journal of Functional Foods, 14, 570-580. https://doi.org/10.1016/j.jff.2015.02.031
Di Costanzo, A. and Angelico, R. (2019) Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art. Molecules, 24, Article 2155. https://doi.org/10.3390/molecules24112155
Leone, F. and Cavalli, R. (2015) Drug Nanosuspensions: A ZIP Tool between Traditional and Innovative Pharmaceutical Formulations. Expert Opinion on Drug Delivery, 12, 1607-1625. https://doi.org/10.1517/17425247.2015.1043886
Kellici, T.F., Ntountaniotis, D., Leonis, G., Chatziathanasiadou, M., Chatzikonstantinou, A.V., Becker-Baldus, J., et al. (2015) Investigation of the Interactions of Silibinin with 2-Hydroxypropyl-β-Cyclodextrin through Biophysical Techniques and Computational Methods. Molecular Pharmaceutics, 12, 954-965. https://doi.org/10.1021/mp5008053
Gharbia, S., Balta, C., Herman, H., Rosu, M., Váradi, J., Bácskay, I., et al. (2018) Enhancement of Silymarin Anti-Fibrotic Effects by Complexation with Hydroxypropyl (HPBCD) and Randomly Methylated (RAMEB) β-Cyclodextrins in a Mouse Model of Liver Fibrosis. Frontiers in Pharmacology, 9, Article 883. https://doi.org/10.3389/fphar.2018.00883
Ma, X. and Williams, R.O. (2018) Polymeric Nanomedicines for Poorly Soluble Drugs in Oral Delivery Systems: An Update. Journal of Pharmaceutical Investigation, 48, 61-75. https://doi.org/10.1007/s40005-017-0372-2
Chen, S., Hao, X., Liang, X., Zhang, Q., Zhang, C., Zhou, G., et al. (2016) Inorganic Nanomaterials as Carriers for Drug Delivery. Journal of Biomedical Nanotechnology, 12, 1-27. https://doi.org/10.1166/jbn.2016.2122
Gillessen, A. and Schmidt, H.H. (2020) Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Advances in Therapy, 37, 1279-1301. https://doi.org/10.1007/s12325-020-01251-y
Anand, A.V., Balamuralikrishnan, B., Kaviya, M., Bharathi, K., Parithathvi, A., Arun, M., et al. (2021) Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including Sars-cov-2. Molecules, 26, Article 1775. https://doi.org/10.3390/molecules26061775
Blaising, J., Lévy, P.L., Gondeau, C., Phelip, C., Varbanov, M., Teissier, E., et al. (2013) Silibinin Inhibits Hepatitis C Virus Entry into Hepatocytes by Hindering Clathrin-Dependent Trafficking. Cellular Microbiology, 15, 1866-1882. https://doi.org/10.1111/cmi.12155
Camini, F.C., da Silva, T.F., da Silva Caetano, C.C., Almeida, L.T., Ferraz, A.C., Alves Vitoreti, V.M., et al. (2018) Antiviral Activity of Silymarin against Mayaro Virus and Protective Effect in Virus-Induced Oxidative Stress. Antiviral Research, 158, 8-12. https://doi.org/10.1016/j.antiviral.2018.07.023
Lani, R., Hassandarvish, P., Chiam, C.W., Moghaddam, E., Chu, J.J., Rausalu, K., et al. (2015) Antiviral Activity of Silymarin against Chikungunya Virus. Scientific Reports, 5, Article No. 11421. https://doi.org/10.1038/srep11421
Dai, J.P., Wu, L.Q., Li, R., Zhao, X.F., Wan, Q.Y., Chen, X.X., et al. (2013) Identification of 23-(s)-2-Amino-3-Phenylpropanoyl-Silybin as an Antiviral Agent for Influenza A Virus Infection in Vitro and in Vivo. Antimicrobial Agents and Chemotherapy, 57, 4433-4443. https://doi.org/10.1128/AAC.00759-13
McClure, J., Margineantu, D.H., Sweet, I.R. and Polyak, S.J. (2014) Inhibition of HIV by Legalon-SIL Is Independent of Its Effect on Cellular Metabolism. Virology, 449, 96-103. https://doi.org/10.1016/j.virol.2013.11.003
Palit, P., Mukhopadhyay, A. and Chattopadhyay, D. (2021) Phyto-Pharmacological Perspective of Silymarin: A Potential Prophylactic or Therapeutic Agent for COVID-19, Based on Its Promising Immunomodulatory, Anti-Coagulant and Anti-Viral Property. Phytotherapy Research, 35, 4246-4257. https://doi.org/10.1002/ptr.7084
Šebera, J., Dubankova, A., Sychrovsky, V., et al. (2018) The Structural Model of Zika Virus RNA-Dependent RNA Polymerase in Complex with RNA for Rational Design of Novel Nucleotide Inhibitors. Scientific Reports, 8, Article No. 11132. https://doi.org/10.1038/s41598-018-29459-7
Rupprecht, C.E. (1996) Rhabdoviruses: Rabies Virus. In: Baron, S., Ed., Medical Microbiology (4th Edition), University of Texas Medical Branch at Galveston, Galveston, Chapter 61. https://www.ncbi.nlm.nih.gov/books/NBK8618/
Kuhn, R.J., Zhang, W., Rossmann, M.G., Pletnev, S.V., Corver, J., Lenches, E., et al. (2018) Structure of Dengue Virus: Implications for Flavivirus Organization, Maturation, and Fusion. Cell, 108, 717-725. https://doi.org/10.1016/S0092-8674(02)00660-8
Ganesan, V.K., Duan, B. and Reid, S.P. (2017) Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses, 9, Article 368. https://doi.org/10.3390/v9120368
Lee, J.E. and Saphire, E.O. (2009) Ebolavirus Glycoprotein Structure and Mechanism of Entry. Future Virology, 4, 621-635. https://doi.org/10.2217/fvl.09.56
Bafna, K., Krug, R.M. and Montelione, G.T. (2020) Structural Similarity of Sars-Cov-2 Mpro and HCV NS3/4A Proteases Suggests New Approaches for Identifying Existing Drugs Useful as COVID-19 Therapeutics. ChemRxiv 2020. https://doi.org/10.26434/chemrxiv.12153615
Biswas, A., Bhattacharjee, U., Chakrabarti, A.K., Tewari, D.N., Banu, H. and Dutta, S. (2020) Emergence of Novel Coronavirus and COVID-19: Whether to Stay or Die out? Critical Reviews in Microbiology, 46, 182-193. https://doi.org/10.1080/1040841X.2020.1739001
Sikander, M., Malik, S., Rodriguez, A., Yallapu, M.M., Narula, A.S., Satapathy, S.K., Dhevan, V., Chauhan, S.C. and Jaggi, M. (2020) Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction. Molecules, 25, Article 5905. https://doi.org/10.3390/molecules25245905
Glowacka, I., Bertram, S., Müller, M.A., Allen, P., Soilleux, E., Pfefferle, S., et al. (2011) Evidence That TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response. Journal of Virology, 85, 4122-4134. https://doi.org/10.1128/JVI.02232-10
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A. and Li, F. (2020) Cell Entry Mechanisms of Sars-Cov-2. Proceedings of the National Academy of Sciences of the United States of America, 117, 11727-11734. https://doi.org/10.1073/pnas.2003138117
Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., et al. (2020) Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion confoRmation. Science, 367, 1260-1263. https://doi.org/10.1126/science.abb2507
Palit, P., Chattopadhyay, D., Thomas, S., Kundu, A., Kim, H.S. and Rezaei, N. (2021) Phytopharmaceuticals Mediated Furin and TMPRSS2 Receptor Blocking: Can It Be a Potential Therapeutic Option for COVID-19? Phytomedicine, 85, Article ID: 153396. https://doi.org/10.1016/j.phymed.2020.153396
Wang, W.Y., Xie, Y., Zhou, H. and Liu, L. (2021) Contribution of Traditional Chinese Medicine to the Treatment of COVID-19. Phytomedicine, 85, Article ID: 153279. https://doi.org/10.1016/j.phymed.2020.153279
Wang, Y., Liu, Y., Lv, Q., Zheng, D., Zhou, L., Ouyang, W., et al. (2021) Effect and Safety of Chinese Herbal Medicine Granules in Patients with Severe Coronavirus Disease 2019 in Wuhan, China: A Retrospective, Single-Center Study with Propensity Score Matching. Phytomedicine, 85, Article ID: 153404. https://doi.org/10.1016/j.phymed.2020.153404
Garg, S., Garg, M., Prabhakar, N., Malhotra, P. and Agarwal, R. (2020) Unraveling the Mystery of Covid-19 Cytokine Storm: From Skin to Organ Systems. Dermatologic Therapy, 33, e13859. https://doi.org/10.1111/dth.13859
Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., et al. (2020) High Risk of Thrombosis in Patients with Severe Sars-Cov-2 Infection: A Multicenter Prospective Cohort Study. Intensive Care Medicine, 46, 1089-1098. https://doi.org/10.1007/s00134-020-06062-x
Penman, S.L., Kiy, R.T., Jensen, R.L., Beoku-Betts, C., Alfirevic, A., Back, D., Khoo, S.H., Owen, A., Pirmohamed, M., Park, B.K., Meng, X., Goldring, C.E. and Chadwick, A.E. (2020) Safety Perspectives on Presently Considered Drugs for the Treatment of COVID-19. British Journal of Pharmacology, 177, 4353-4374. https://doi.org/10.1111/bph.15204
Toyoshima, Y., Nemoto, K., Matsumoto, S., et al. (2020) SARS-CoV-2 Genomic Variations Associated with Mortality Rate of COVID-19. Journal of Human Genetics, 65, 1075-1082. https://doi.org/10.1038/s10038-020-0808-9
Severe Covid-19 GWAS Group, Ellinghaus, D., Degenhardt, F., Bujanda, L., Buti, M., Albillos, A., et al. (2020) Genomewide Association Study of Severe Covid-19 with Respiratory Failure. The New England Journal of Medicine, 383, 1522-1534. https://doi.org/10.1056/NEJMoa2020283
Carter, C., Thi Lan Anh, N. and Notter, J. (2020) COVID-19 Disease: Perspectives in Low- and Middle-Income Countries. Clinics in Integrated Care, 1, Article ID: 100005. https://doi.org/10.1016/j.intcar.2020.100005
Renu, K., Prasanna, P.L. and Valsala Gopalakrishnan, A. (2020) Coronaviruses Pathogenesis, Comorbidities and Multi-Organ Damage—A Review. Life Sciences, 255, Article ID: 117839. https://doi.org/10.1016/j.lfs.2020.117839
Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S. and Yuen, K.Y. (2016) Coronaviruses—Drug Discovery and Therapeutic Options. Nature Reviews Drug Discovery, 15, 327-347. https://doi.org/10.1038/nrd.2015.37
Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., et al. (2020) Risk Factors for Severity and Mortality in Adult COVID-19 Inpatients in Wuhan. J Allergy Clin Immunol 2020, 146, 110-118. https://doi.org/10.1016/j.jaci.2020.04.006
Al-Samkari, H., Karp Leaf, R.S., Dzik, W.H., Carlson, J.C., Fogerty, A.E., Waheed, A., et al. (2020) COVID and Coagulation: Bleeding and Thrombotic Manifestations of Sars-Cov-2 Infection. Blood, 136, 489-500. https://doi.org/10.1182/blood.2020006520
Coppola, A., Lombardi, M., Tassoni, M.I., Carolla, G., Tala, M., Morandini, R., et al. (2020) COVID-19, Thromboembolic Risk and Thromboprophylaxis: Learning Lessons from the Bedside, Awaiting Evidence. Blood Transfusion, 18, 226-229.
Lemke, G. and Silverman, G.J. (2020) Blood Clots and TAM Receptor Signalling in COVID-19 Pathogenesis. Nature Reviews Immunology, 20, 395-396. https://doi.org/10.1038/s41577-020-0354-x
Fakhri, S., Piri, S., Majnooni, M.B., Farzaei, M.H. and Echeverría, J. (2021) Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach. Frontiers in Pharmacology, 20, Article 621099. https://doi.org/10.3389/fphar.2020.621099
Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., et al. (2020) China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720. https://doi.org/10.1056/NEJMoa2002032
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet, 395, 507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Bellik, Y., Hammoudi, S.M., Abdellah, F., Iguer-Ouada, M. and Boukraa, L. (2012) Phytochemicals to Prevent Inflammation and Allergy. Recent Patents on Inflammation & Allergy Drug Discovery, 6, 147-158. https://doi.org/10.2174/187221312800166886
Favarin, D.C., de Oliveira, J.R., de Oliveira, C.J. and Rogerio Ade, P. (2013) Potential Effects of Medicinal Plants and Secondary Metabolites on Acute Lung Injury. BioMed Research International, 2013, Article ID: 576479. https://doi.org/10.1155/2013/576479
Majnooni, M.B., Fakhri, S., Shokoohinia, Y., Kiyani, N., Stage, K., Mohammadi, P., et al. (2020) Phytochemicals: Potential Therapeutic Interventions against Coronavirus-Associated Lung Injury. Frontiers in Pharmacology, 11, Article 588467. https://doi.org/10.3389/fphar.2020.588467
Karimi, G., Vahabzadeh, M., Lari, P., Rashedinia, M. and Moshiri, M. (2011) “Silymarin”, a Promising Pharmacological Agent for Treatment of Diseases. Iranian Journal of Basic Medical Sciences, 14, 308-317.
Sahibzada, M.U.K., Sadiq, A., Khan, S., Faidah, H.S., Naseemullah Khurram, M., et al. (2017) Fabrication, Characterization and in Vitro Evaluation of Silibinin Nanoparticles: An Attempt to Enhance Its Oral Bioavailability. Drug Design, Development and Therapy, 11, 1453-1464. https://doi.org/10.2147/DDDT.S133806
Sardanelli, A.M., Isgrò, C. and Palese, L.L. (2021) Sars-Cov-2 Main Protease Active Site Ligands in the Human Metabolome. Molecules, 26, Article 1409. https://doi.org/10.3390/molecules26051409
Speciale, A., Muscarà, C., Molonia, M.S., Cimino, F., Saija, A. and Giofrè, S.V. (2021) Silibinin as Potential Tool against Sars-Cov-2: In Silico Spike Receptor-Binding Domain and Main Protease Molecular Docking Analysis, and in Vitro Endothelial Protective Effects. Phytotherapy Research, 35, 4616-4625. https://doi.org/10.1002/ptr.7107
Kumar, S., Kashyap, P., Chowdhury, S., Kumar, S., Panwar, A. and Kumar, A. (2021) Identification of Phytochemicals as Potential Therapeutic Agents That Binds to Nsp15 Protein Target of Coronavirus (Sars-Cov-2) That Are Capable of Inhibiting Virus Replication. Phytomedicine, 85, Article ID: 153317. https://doi.org/10.1016/j.phymed.2020.153317